EA200300439A1 - Мутанты хемокинов при лечении рассеянного склероза - Google Patents

Мутанты хемокинов при лечении рассеянного склероза

Info

Publication number
EA200300439A1
EA200300439A1 EA200300439A EA200300439A EA200300439A1 EA 200300439 A1 EA200300439 A1 EA 200300439A1 EA 200300439 A EA200300439 A EA 200300439A EA 200300439 A EA200300439 A EA 200300439A EA 200300439 A1 EA200300439 A1 EA 200300439A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mutants
treatment
multiple sclerosis
hemokin
chemokines
Prior art date
Application number
EA200300439A
Other languages
English (en)
Other versions
EA006137B1 (ru
Inventor
Аманда Праудфут
Тимоти Н.К. Уэллс
Мари Коско-Вильбуа
Original Assignee
Апплайд Резеч Системз Арс Холдинг Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Апплайд Резеч Системз Арс Холдинг Н.В. filed Critical Апплайд Резеч Системз Арс Холдинг Н.В.
Publication of EA200300439A1 publication Critical patent/EA200300439A1/ru
Publication of EA006137B1 publication Critical patent/EA006137B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Мутанты СС-хемокинов, которые содержат, по меньшей мере, две мутации в катионном сайте петли 40-х положений аминокислот и которые по сравнению с молекулой дикого типа обладают пониженной GAG-связывающей активностью. В частности, было установлено, что такие мутантные хемокины являются эффективными при лечении рассеянного склероза и/или других демиелинизирующих заболеваний. Тройной мутант RANTES представляет соединение, показывающее наилучшие результаты.Отчет о международном поиске был опубликован 2002.06.13.
EA200300439A 2000-10-04 2001-10-03 Мутантный хемокин rantes человека и применение мутантных хемокинов для лечения рассеянного склероза EA006137B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00121665 2000-10-04
PCT/EP2001/011428 WO2002028419A2 (en) 2000-10-04 2001-10-03 Chemokine mutants in the treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
EA200300439A1 true EA200300439A1 (ru) 2003-08-28
EA006137B1 EA006137B1 (ru) 2005-10-27

Family

ID=8170011

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300439A EA006137B1 (ru) 2000-10-04 2001-10-03 Мутантный хемокин rantes человека и применение мутантных хемокинов для лечения рассеянного склероза

Country Status (31)

Country Link
US (1) US7402303B2 (ru)
EP (1) EP1326628B1 (ru)
JP (1) JP3908165B2 (ru)
KR (1) KR100837898B1 (ru)
CN (1) CN1285381C (ru)
AR (1) AR030854A1 (ru)
AT (1) ATE265222T1 (ru)
AU (2) AU2002215919B2 (ru)
BG (1) BG66137B1 (ru)
BR (1) BR0114407A (ru)
CA (1) CA2423616C (ru)
CZ (1) CZ303409B6 (ru)
DE (1) DE60103078T2 (ru)
DK (1) DK1326628T3 (ru)
EA (1) EA006137B1 (ru)
EE (1) EE05174B1 (ru)
ES (1) ES2217199T3 (ru)
HK (1) HK1062811A1 (ru)
HR (1) HRP20030215B1 (ru)
HU (1) HUP0302194A3 (ru)
IL (2) IL155178A0 (ru)
MX (1) MXPA03003008A (ru)
NO (1) NO330278B1 (ru)
PL (1) PL204231B1 (ru)
PT (1) PT1326628E (ru)
RS (1) RS50738B (ru)
SI (1) SI1326628T1 (ru)
SK (1) SK287523B6 (ru)
UA (1) UA77950C2 (ru)
WO (1) WO2002028419A2 (ru)
ZA (1) ZA200302315B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525089A (ja) 2001-12-17 2005-08-25 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ ケモカイン・アンタゴニストとして作用するケモカイン突然変異体
DE60303929T2 (de) * 2002-04-04 2006-08-10 Applied Research Systems Ars Holding N.V. Chemokin-muntanten mit verbesserter oraler bioverfügbarkeit
WO2004062688A2 (en) * 2002-12-23 2004-07-29 Applied Research Systems Ars Holding N.V. Use of cc-chemokine mutants against liver diseases
DE602004018014D1 (de) * 2003-10-22 2009-01-08 Serono Lab Cxcl8-antagonisten
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
DE60304435T2 (de) * 2004-01-19 2006-08-24 Ares Trading S.A. Verfahren zur Reinigung von in Bakterien exprimierten Proteinen
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
EP1760110B1 (en) * 2005-09-03 2011-11-02 Samsung SDI Co., Ltd. Polybenzoxazine-based compound, electrolyte membrane including the same, and fuel cell employing the electrolyte membrane
GB0614755D0 (en) 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
MX2010001307A (es) 2007-08-02 2010-07-30 Novimmune Sa Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
AU2011213559B2 (en) * 2010-02-08 2015-05-07 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding RANTES, and compositions comprising and methods of using the same
CA3101052A1 (en) 2018-05-28 2019-12-05 ORION Biotechnology Switzerland Sarl Methods of inhibiting cerebral inflammation
WO2022093857A1 (en) * 2020-10-26 2022-05-05 City Of Hope Oncolytic virus compositions and methods for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1998006751A1 (en) * 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists
EP0906954A1 (en) * 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
DE69832216T2 (de) * 1997-12-23 2006-05-24 Fondazione Centro San Raffaele Del Monte Tabor RANTES-Mutanten und therapeutische Anwendungen davon
AU2740900A (en) * 1999-01-29 2000-08-18 Millennium Pharmaceuticals, Inc. Method of treating demyelinating inflammatory disease using ccr1 antagonists

Also Published As

Publication number Publication date
SK4062003A3 (en) 2003-08-05
HRP20030215B1 (en) 2011-09-30
HK1062811A1 (en) 2004-11-26
HUP0302194A3 (en) 2005-12-28
CN1477969A (zh) 2004-02-25
PT1326628E (pt) 2004-09-30
AU1591902A (en) 2002-04-15
MXPA03003008A (es) 2003-07-14
ES2217199T3 (es) 2004-11-01
EP1326628B1 (en) 2004-04-28
NO330278B1 (no) 2011-03-21
WO2002028419A2 (en) 2002-04-11
SI1326628T1 (en) 2004-10-31
PL204231B1 (pl) 2009-12-31
RS50738B (sr) 2010-08-31
CA2423616C (en) 2010-03-16
WO2002028419A3 (en) 2002-06-13
NO20031525L (no) 2003-04-03
SK287523B6 (sk) 2011-01-04
DE60103078D1 (de) 2004-06-03
EA006137B1 (ru) 2005-10-27
NO20031525D0 (no) 2003-04-03
ATE265222T1 (de) 2004-05-15
DK1326628T3 (da) 2004-08-09
PL362350A1 (en) 2004-10-18
BR0114407A (pt) 2003-07-29
UA77950C2 (en) 2007-02-15
US7402303B2 (en) 2008-07-22
HUP0302194A2 (hu) 2003-10-28
CZ2003947A3 (cs) 2003-11-12
US20040101509A1 (en) 2004-05-27
AU2002215919B2 (en) 2005-11-24
JP2004510426A (ja) 2004-04-08
IL155178A (en) 2009-07-20
JP3908165B2 (ja) 2007-04-25
AR030854A1 (es) 2003-09-03
BG107685A (bg) 2003-11-28
CA2423616A1 (en) 2002-04-11
HRP20030215A2 (en) 2005-02-28
CZ303409B6 (cs) 2012-09-05
IL155178A0 (en) 2003-11-23
DE60103078T2 (de) 2005-04-07
EE05174B1 (et) 2009-06-15
YU25703A (sh) 2006-05-25
EE200300139A (et) 2003-06-16
ZA200302315B (en) 2004-03-25
BG66137B1 (bg) 2011-07-29
EP1326628A2 (en) 2003-07-16
KR100837898B1 (ko) 2008-06-13
KR20030034238A (ko) 2003-05-01
CN1285381C (zh) 2006-11-22

Similar Documents

Publication Publication Date Title
EA200300439A1 (ru) Мутанты хемокинов при лечении рассеянного склероза
EA200500472A1 (ru) Ацетил 2-гидрокси-1,3-диаминоалканы
GEP20022678B (en) Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibitors, their Pharmaceutical compositions and methods for Treatment
EA199900778A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ИСПОЛЬЗОВАНИЕ ДЛЯ ИНГИБИРОВАНИЯ β-АМИЛОИДНОГО ПЕПТИДА
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
EA200400648A1 (ru) N, n'-замещенные производные 1,3-диамино-2-гидроксипропана
MXPA05001096A (es) Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
NZ305940A (en) N-(aroyl)glycine hydroxamic acid derivatives and related compounds that inhibit the production of tnf and are useful in treating asthma
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
NO330934B1 (no) Flytende farmasoytisk preparat samt anvendelse og fremstilling derav.
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
FI925787A (fi) Proteolytiska enzymers sackarinderivatinhibitorer
MXPA04003245A (es) Hidroxipropilaminas.
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
EA200301253A1 (ru) Применение остеопонтина для лечения и/или профилактики неврологических заболеваний
TW200505828A (en) Substituted ureas and carbamates useful in the treatment of alzheimer's disease
EP0911331A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
EA200000379A1 (ru) Усеченные по амино-концу rantes как антагонисты хемокинов
RU94041224A (ru) Пептиды с органозащитной активностью, фармацевтическая композиция на их основе и их применение в терапии
WO2000009553A3 (en) Antimicrobial peptides isolated from the skin of american frogs
ES2107033T3 (es) Peptidos bpc, su preparacion y su utilizacion.
EA199900385A1 (ru) Соединения 1-арил-2-ациламиноэтана и их применение в качестве антагонистов нейрокинина, в частности нейрокинина 1
ATE111484T1 (de) Verbindungen zur verhinderung von thrombose.
CA2020663A1 (en) Substitution analogues of magainin peptides
EA199700199A1 (ru) 4-аминотетрагидробензизоксазоловые или -изотиазоловые соединения, их применение и фармацевтическая композиция на их основе

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU